indic improv sale foreign tourist
demand issu product maintain outperform
updat pediatr clinic data expect eha
surpris sickl cell updat eha
navig confer takeaway forefront ident
fda approv aimovig erenumab price
abstract posit develop support
present preclin data new ex-vivo cell therapi program
cerdulatinib abstract impress come
analyst certif import disclosur see
datatim may enterpris interest blockchain
young punk get lawn thought cod
paypal announc acquisit izettl
in-lin quarter reason optimist
indic improv sale foreign tourist
earli may report entitl posit momentum still build note reiter outperform rate
lift price target share crux posit nearer term argument new senior leadership
spur note activist investor potenti unlock meaning improv financi result better leverag underli
power luxuri brand monitor number key variabl earlier week call mark improv sale
intern tourist contributor stronger top-lin trend increasingli optimist strengthen macro backdrop includ
better foreign shopper spend could make even conduc recoveri environ
demand issu product maintain outperform
recent investor meet newli appoint ceo david maura emphas major spb ailment self-inflict
fact order book strong production/ship issu improv guidanc appear reason catalyst abound hrg deal
close end june batteri sale close announc applianc buyer happen
next two three month transact give cash meaning delev repurchas share outstand
revis adjust ep reflect previou buyback maintain outperform lower pt
owe lower group multipl
updat pediatr clinic data expect eha
thursday global blood announc five poster present schedul european hematolog associ eha meet june one
present includ updat clinic result pediatr sickl cell diseas scd patient enrol on-going phase
hope-kid studi hematolog result patient includ abstract point reduc hemolysi ten show
increas hemoglobin level baselin week cohort receiv mg voxelotor daili display seriou treatment-rel
patient-report symptom sever score trend lower rel baselin await part result compani pivot
studi expect within week believ new data reinforc voxelotor benefici impact scd patient mild safeti profil
surpris sickl cell updat eha
thursday bluebird announc two upcom oral present schedul annual european hematolog associ eha congress
featur clinic updat on-going studi lentiglobin sever sickl cell diseas scd transfusion-depend
thalassemia tdt manag previous guid updat would reserv view earli
updat posit sign late compani act quickli present first clinic result ahead investor expect
major updat come june data-rich month bluebird three major value-driv program
posit result one program could potenti off-set disappoint result anoth remain sidelin perform
rate pt
week print atc provid better visibl value-ad servic va cross-sel regul headwind
net revenu guidanc rang opco/street y/i repres strong indic ctrp effect manag near-
term va difficulti view believ va regul impact travel supplier ctrp best posit eventu emerg
greater market share would lt buyer weak accommod revenu key metric guid deceler
support meituan/baba competit concern howev believ ctrp custom servic employe suppli scale
provid strong moat combat emerg player maintain outperform price target
navig confer takeaway forefront ident govern innov
follow navig confer remain bullish compani uniqu posit within grow ident market base
follow believ continu benefit strong industri tailwind ident pervas cloud/saa
autom stricter complianc oblig new flexibl deploy model on-premis cloud-host msp
multi-environ data analyt capabl new securityiq upgrad tackl necessari ident govern requir
believ sustain strong momentum within mid- large-enterpris market believ remain lead innov
increasingli relev market space support long-term posit thesi sail lock-up period expir wednesday view
recent pullback solid entri point reiter outperform
fda approv aimovig erenumab price expect
time aimovig approv line expect gross price annual similar estim net
price addit time price support expect aimovig report migrain survey june support view
aimovig adopt treatment migrain quickli launch anticip aimovig launch result
sale million product sale sale level base conserv market adopt therefor may upsid
estim
abstract posit develop support outlook
abstract releas may one part one part data preliminari clinic result
on-going phase i/ii trial evalu time result expect progress part
present asco abstract support view cytomx advanc file fda
outlook remain unchang poster abstract detail initi result two on-going dose escal arm proclaim-
trial monotherapi combin yervoy ipilimumab patient advanc unresect solid tumor
present preclin data new ex-vivo cell therapi program
intellia announc may first ex-vivo t-cell therapi target treatment acut myeloid leukemia aml
believ ex-vivo therapi lower risk approach use crispr therapeut newli announc aml program still earli stage
believ import develop intellia
thursday biolinerx announc new data two on-going clinic studi slate present june european
hematolog associ eha congress one trial investig hematopoiet stem cell mobil allogen transplant
top-lin data show singl therapeut dose mobil suffici cell transplant suggest drug could serv
altern standard-of-car g-csf believ result underscor util mobil could de-risk on-going phase
genesi trial primari valu driver also evalu varieti cancer expect see long-term follow-up
prior studi r/r aml eha reiter outperform rate pt
cerdulatinib abstract impress come
eha abstract cerdulatinib post on-line provid increment insight promis profil under-appreci asset
cerdulatinib oral avail dual-kinas inhibitor hematolog malign believ cerdulatinib potenti benefit patient
fl cll/sll base clinic data contain eha abstract featur result patient on-going
trial cerdulatinib b-cell malign see cerdulatinib overlook well-differenti asset impress
preliminari data deliv increment sharehold valu expect see updat cerdulatinib data eha base
recent data cut theoret sotp valuat includ cerdulatinib believ could increas post-asco eha
grow demand stop nand flash price fall digitim
global pc sale hit bottom digitim
china approv toshiba sale billion chip unit bain consortium reuter
datatim may enterpris interest blockchain build
attend consensu focu cloud player reduc blockchain deploy complex acceler enterpris adopt
vonag focu largest custom materi compani move upmarket
verizon analyst day monday like focu
top monthli pick expect continu das/wholesale/militari momentum
emerg technolog servic
young punk get lawn thought cod
activis host call duti commun reveal event latest instal franchis black op releas
met expect pc battl net support focu game play mechan multi-play mode like battl royal continu
believ biggest cod cornerston deeper esport integr mani year cod
titl get play well past expir believ one treyarch discuss featur attract new
player believ game posit appeal wider younger player like fortnit instead believ game built
best-in-class hardcor fp player share gain come titl cs go sieg pubg battlefield okay
player base overal learn saw give investor comfort cod continu grow remain
paypal announc acquisit izettl
paypal announc agreement purchas izettl cash izettl smb-focus payment processor similar squar
oper market europ latam izettl add merchant tpv broaden in-stor omni-channel
capabl izettl anticip net revenu stand-alon profit appreci strateg rational
acquisit believ effect alloc small portion perhap capit flexibl consid synchroni deal
acquisit deepen smb capabl offer signific cross-sel potenti merchant custom maintain outperform
rais pt
total revenu exceed expect grew y/i strong truck brokerag oper environ favor demand/pr
trend tight capac nast segment truckload price increas y/i volum declin y/i net revenu margin
contract y/i y/i vs y/i nast segment net revenu margin declin y/i truckload expens
growth outpac price growth total net revenu grew y/i respect oper incom grew
y/i expect modifi ep higher revenu outlook off-set greater increas
oper expens sidelin pend sign sustain strong oper incom growth opportun entri point
in-lin quarter reason optimist
like ecc busi model let investor take focus bet credit equiti vehicl equiti risk equity-lik
return come form annual dividend/yield still like busi model note even quit
expect long slow spread compress leverag loan market make quit dent portfolio yield result
compani under-earn dividend net invest incom confid manag pull everi lever
mitig time yield thu incom improv investor patient
